Worta McCaskill-Stevens
#183,411
Most Influential Person Now
American physician-scientist and medical oncologist
Worta McCaskill-Stevens's AcademicInfluence.com Rankings
Worta McCaskill-Stevensmedical Degrees
Medical
#3832
World Rank
#4351
Historical Rank
#577
USA Rank
Oncology
#279
World Rank
#288
Historical Rank
#30
USA Rank
Worta McCaskill-Stevensphilosophy Degrees
Philosophy
#12197
World Rank
#16907
Historical Rank
#2372
USA Rank
Logic
#9067
World Rank
#11436
Historical Rank
#1562
USA Rank
Download Badge
Medical Philosophy
Why Is Worta McCaskill-Stevens Influential?
(Suggest an Edit or Addition)According to Wikipedia, Worta J. McCaskill-Stevens was an American physician-scientist and medical oncologist specialized in cancer disparities research, management of comorbidities within clinical trials, and molecular research for cancer prevention interventions. She was chief of the community oncology and prevention trials research group at the National Cancer Institute.
Worta McCaskill-Stevens's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010) (594)
- Multidisciplinary meeting on male breast cancer: summary and research recommendations. (2010) (386)
- Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. (2006) (326)
- Projecting individualized absolute invasive breast cancer risk in African American women. (2007) (306)
- Participation of Minorities in Cancer Research (2000) (257)
- Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. (2003) (253)
- Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. (2012) (237)
- Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. (2000) (221)
- A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. (1996) (204)
- Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. (2009) (180)
- Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. (2011) (170)
- Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. (2019) (166)
- The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial (2009) (148)
- Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. (1999) (120)
- Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. (2011) (113)
- The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. (2013) (110)
- The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) (103)
- Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. (2017) (100)
- Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. (1999) (99)
- Barriers to racial/ethnic minority application and competition for NIH research funding. (2005) (93)
- Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. (2013) (89)
- Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. (2005) (87)
- Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program (2014) (84)
- Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. (2000) (71)
- Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 (2013) (65)
- Translating research into evidence‐based practice (2010) (58)
- Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. (1994) (54)
- Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. (2015) (48)
- p53 as a Marker of Prognosis in African-American Women with Breast Cancer (2010) (48)
- Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients (2003) (46)
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
- Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology. (2015) (45)
- Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. (2020) (42)
- Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop. (2015) (41)
- My Lived Experiences Are More Important Than Your Probabilities (2014) (40)
- Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. (1995) (39)
- Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. (2014) (37)
- Creating a “culture of research” in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program (2015) (33)
- Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute (2017) (32)
- Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. (2017) (31)
- Challenges in ductal carcinoma in situ risk communication and decision‐making (2012) (31)
- Challenges and recommendations for advancing the state‐of‐the‐science of quality of life assessment in symptom management trials (2007) (27)
- Breast Cancer Risk Assessments Comparing Gail and CARE Models in African‐American Women (2009) (26)
- Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. (2004) (22)
- Promoting cancer screening among the first-degree relatives of breast and colorectal cancer patients: the design of two randomized trials. (1999) (21)
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities (2013) (20)
- The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. (2006) (20)
- A critical review of the enrollment of black patients in cancer clinical trials. (2012) (19)
- The NCI Community Oncology Research Program: what every clinician needs to know. (2013) (19)
- Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. (2019) (18)
- Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial (2010) (18)
- Evolution of Cancer Care Delivery Research in the NCI Community Oncology Research Program. (2019) (17)
- Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. (2022) (17)
- Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. (2010) (17)
- NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction (2017) (16)
- Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study. (2015) (14)
- COVID-19, Social Justice, and Clinical Cancer Research (2020) (13)
- Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes? (2011) (13)
- Breast cancer prevention: the next steps. (2000) (12)
- Reporting of health‐related quality of life endpoints in National Cancer Institute–supported cancer treatment trials (2020) (12)
- Chemoprevention for breast cancer. (2012) (12)
- Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank (2016) (12)
- Tomosynthesis mammographic Imaging Screening Trial (TMIST): An Invitation and Opportunity for the National Medical Association Community to Shape the Future of Precision Screening for Breast Cancer. (2020) (11)
- National Cancer Institute--supported cancer chemoprevention research: coming of age. (1999) (10)
- Race and the Prognostic Influence of p53 in Women with Breast Cancer (2012) (10)
- Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results (2019) (10)
- Chemoprevention for breast cancer: overcoming barriers to treatment. (2012) (10)
- Cooperative Group Trials in the Community Setting. (2015) (10)
- Learning from experience. (2009) (8)
- Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS). (2021) (8)
- SI RLTD: Risk Scores and Decision Making: The Anatomy of a Decision to Reduce Breast Cancer Risk. (2010) (8)
- Use of a clinical trial screening tool to enhance patient accrual (2021) (7)
- Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study. (2017) (7)
- National Institutes of Health State-of-the-Science Conference on the Management and Diagnosis of Ductal Carcinoma in Situ: a call to action. (2010) (6)
- Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community. (2016) (6)
- The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial (2008) (6)
- Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (2015) (6)
- DeImplementing Ineffective and Low-Value Clinical Practices: Research and Practice Opportunities in Community Oncology Settings. (2021) (5)
- Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1 (2019) (5)
- A Report of the Women's Health Congress Workshop on The Health of Women of Color: A Critical Intersection at the Corner of Sex/Gender and Race/Ethnicity (2016) (5)
- Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). (2014) (5)
- OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43. (2011) (4)
- Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico (2018) (4)
- Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine. (2015) (4)
- Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. (2020) (4)
- Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. (2011) (3)
- A phase i trial of subcutaneous (SC) BB-10010 in breast. Cancer patients (PTS) receiving high-dose cyclophosphamide (C) (1996) (3)
- Other- and all-cause Mortality among women with breast cancer. (2020) (3)
- Adjuvant chemotherapy for node-negative breast cancer. (1992) (3)
- Abstract P6-10-01: Results from NRG oncology/NSABP protocol DMP-1: Women's decision-making in breast cancer risk reduction (2016) (2)
- The clinical trial assessment of infrastructure matrix tool (CT AIM) to improve the quality of research conduct in the community. (2014) (2)
- Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. (2007) (2)
- Impact of comorbidity and age on treatment choice among men with localized prostate cancer. (2019) (2)
- Randomized trial of lisinopril or carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving trastuzumab. (2018) (2)
- Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients (2020) (2)
- Refining the clinical trials assessment of infrastructure matrix tool. (2014) (1)
- Establishing a Primary Care Alliance for Conducting Cancer Prevention Clinical Research at Community Sites (2021) (1)
- NCI’s national treatment trial networks: Experience and adaptations during COVID-19. (2021) (1)
- National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers. (2017) (1)
- Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43. (2011) (1)
- p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer (2006) (1)
- Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). (2011) (1)
- Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration. (2022) (1)
- Abstract PO-092: Expanded access trial of tocilizumab in COVID19+ hospitalized cancer patients (2020) (1)
- Absence of racial predilection for aggressive tumor phenotype among low socio-economic status women with breast cancer (2007) (0)
- A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43. (2012) (0)
- p53 as an additional marker to the intrinsic subtype classification as a method to further stratify breast cancer survival in African American (AA) women (2008) (0)
- Oncologists’ perceived confidence in managing pre-existing chronic comorbidities during patients’ active cancer treatment. (2019) (0)
- Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer. (2010) (0)
- Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%). (2021) (0)
- A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). (2010) (0)
- OP-JNCI190248 557..561 (2020) (0)
- Abstract B034: Time to treatment and overall survival among men with localized prostate cancer (2018) (0)
- Abstract B120: Identifying cancer disparities research gaps in NCORP: A pilot portfolio analysis (2023) (0)
- Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment (2023) (0)
- The NCI Community Cancer Centers Program (NCCCP): A model for reducing cancer health care disparities. (2012) (0)
- Weighing the Benefits and Risks in Clinical Trials and Practice (2001) (0)
- Analysis of minority-based community clinical oncology program (MBCCOP) accrual activity. (2011) (0)
- Decision-making in breast cancer risk reduction: Results from a nested qualitative study from NRG Oncology/NSABP protocol DMP-1. (2015) (0)
- Abstract PL06-03: Lessons learned through the minority-based community clinical oncology program (2009) (0)
- p53 as a marker of prognosis in African American (AA) women with breast cancer. (2009) (0)
- Results from NRG oncology/NSABP protocol DMP-1: Physician counseling. (2018) (0)
- The influence of sociodemographic factors on breast cancer tumor biology. (2011) (0)
- Abstract D079: Oncologists’ approach in managing pre-existing chronic comorbidities during patients’ active cancer treatment (2020) (0)
- Use of a clinical trials screening tool in the NCI Community Oncology Research Program (NCORP) to enhance accrual and promote disparities research. (2019) (0)
- Community and academic partnerships: Moving a new generation of clinical trials in NCI Community Oncology Research Program (NCORP) into community oncology practices. (2019) (0)
- Chemotherapy for Breast Cancer: How Are We Doing? Can We Do Better? (1996) (0)
- Determinants of participation in the Study of Tamoxifen and Raloxifene (STAR): Experience of a minority-based community oncology program (2005) (0)
- Abstract 859: Race-based survival and prognosis among lower SES women with ER/PR negative breast cancer (2010) (0)
This paper list is powered by the following services:
Other Resources About Worta McCaskill-Stevens
What Schools Are Affiliated With Worta McCaskill-Stevens?
Worta McCaskill-Stevens is affiliated with the following schools:
